(thirdQuint)Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children.

 The subjects in this study will be allocated to the same groups as in study MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (NCT00955682).

 No vaccine will be administered during this long-term persistence study.

.

 Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children@highlight

The purpose of this study is to evaluate the long-term antibody persistence as well as safety of GSK Biologicals' MenACWY-TT vaccine versus Meningitec up to 6 years after booster vaccination administered in healthy 5 year old children in the study MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (NCT00955682), who were primed with the same vaccine in the study MENACWY-TT-039 (NCT00474266) at 12 through 23 months of age.

